Fig. 4: ctDNA assessment during the TNT and the follow-up.

A Proportion of patients with scCR depending on the detection of ctDNA and the respective TF at the P1 and P2 timepoints; the highest available value between P1 and P2 was used for this purpose. B Kaplan–Meier curves depicting DFS depending on the detection of ctDNA and the respective TF at the P1 and P2 timepoints; DFS was measured starting from the moment of the liquid biopsy blood withdrawal; the highest available value between P1 and P2 was used for this purpose; C Proportion of patients with scCR depending on the detection of ctDNA and the respective TF at the F1 timepoint; for this panel, only patients proposed for WW observation were considered; D Kaplan–Meier curves depicting DFS depending on the detection of ctDNA and the respective TF at the F1 timepoint; DFS was measured starting from the moment of the liquid biopsy blood withdrawal; E TF across all available timepoints; each line is a patient, colored depending on the presence of disease relapse; the dashed line represent the 0.01% cut-off; F TF of all follow-up timepoints depending on the disease relapse timing; the p-value was calculated using Wilcoxon signed-rank test; for graphic purposes, a sample with undetected ctDNA was plotted as TF = 0.001%. ctDNA circulating tumor DNA, DFS disease-free survival, scCR sustained clinical complete response.